targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000037280 | MONDO_0021640 | NCT00923117 | Terminated | 2 | 2008-06-01 | Terminated | stopped | null | null | Phase II+ | 180,388,627,053 | The study was terminated based on results of an interim analysis for futility. | Phase 2 | 30/06/2008 | Terminated | 30/09/2015 | 30/06/2012 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | cancer_gene_census | somatic_mutation | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT00923117 | Terminated | 2 | 2008-06-01 | Terminated | stopped | null | null | Phase II+ | 180,388,627,053 | The study was terminated based on results of an interim analysis for futility. | Phase 2 | 30/06/2008 | Terminated | 30/09/2015 | 30/06/2012 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT00923117 | Terminated | 2 | 2008-06-01 | Terminated | stopped | null | null | Phase II+ | 180,388,627,053 | The study was terminated based on results of an interim analysis for futility. | Phase 2 | 30/06/2008 | Terminated | 30/09/2015 | 30/06/2012 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | cancer_gene_census | somatic_mutation | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT00923117 | Terminated | 2 | 2008-06-01 | Terminated | stopped | null | null | Phase II+ | 180,388,627,053 | The study was terminated based on results of an interim analysis for futility. | Phase 2 | 30/06/2008 | Terminated | 30/09/2015 | 30/06/2012 | Negative | Negative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT03275558 | Withdrawn | 1 | 2018-07-17 | Withdrawn | stopped | null | null | null | 1,382,979,470,027 | Study halted prior to enrollment of first participant. (It has been determined on 2018 May 15 that the NCT03275558 study will be stopped by sponsor decision) | Phase 1 | 17/07/2018 | Withdrawn | 19/07/2018 | 17/07/2018 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | cancer_gene_census | somatic_mutation | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT03275558 | Withdrawn | 1 | 2018-07-17 | Withdrawn | stopped | null | null | null | 1,382,979,470,027 | Study halted prior to enrollment of first participant. (It has been determined on 2018 May 15 that the NCT03275558 study will be stopped by sponsor decision) | Phase 1 | 17/07/2018 | Withdrawn | 19/07/2018 | 17/07/2018 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT03275558 | Withdrawn | 1 | 2018-07-17 | Withdrawn | stopped | null | null | null | 1,382,979,470,027 | Study halted prior to enrollment of first participant. (It has been determined on 2018 May 15 that the NCT03275558 study will be stopped by sponsor decision) | Phase 1 | 17/07/2018 | Withdrawn | 19/07/2018 | 17/07/2018 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | cancer_gene_census | somatic_mutation | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT03275558 | Withdrawn | 1 | 2018-07-17 | Withdrawn | stopped | null | null | null | 1,382,979,470,027 | Study halted prior to enrollment of first participant. (It has been determined on 2018 May 15 that the NCT03275558 study will be stopped by sponsor decision) | Phase 1 | 17/07/2018 | Withdrawn | 19/07/2018 | 17/07/2018 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT03275558 | Withdrawn | 1 | 2018-07-17 | Withdrawn | stopped | null | null | null | 1,382,979,470,027 | Study halted prior to enrollment of first participant. (It has been determined on 2018 May 15 that the NCT03275558 study will be stopped by sponsor decision) | Phase 1 | 17/07/2018 | Withdrawn | 19/07/2018 | 17/07/2018 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | cancer_gene_census | somatic_mutation | 413,311 |
ENSG00000037280 | MONDO_0021640 | NCT03275558 | Withdrawn | 1 | 2018-07-17 | Withdrawn | stopped | null | null | null | 1,382,979,470,027 | Study halted prior to enrollment of first participant. (It has been determined on 2018 May 15 that the NCT03275558 study will be stopped by sponsor decision) | Phase 1 | 17/07/2018 | Withdrawn | 19/07/2018 | 17/07/2018 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03772561 | Recruiting | 1 | 2018-12-03 | null | null | null | null | null | 309,237,645,462 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03772561 | Recruiting | 1 | 2018-12-03 | null | null | null | null | null | 309,237,645,462 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03772561 | Recruiting | 1 | 2018-12-03 | null | null | null | null | null | 309,237,645,462 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03772561 | Recruiting | 1 | 2018-12-03 | null | null | null | null | null | 309,237,645,462 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03772561 | Recruiting | 1 | 2018-12-03 | null | null | null | null | null | 309,237,645,462 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03772561 | Recruiting | 1 | 2018-12-03 | null | null | null | null | null | 309,237,645,462 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03772561 | Recruiting | 1 | 2018-12-03 | null | null | null | null | null | 309,237,645,462 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03772561 | Recruiting | 1 | 2018-12-03 | null | null | null | null | null | 309,237,645,462 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03772561 | Recruiting | 1 | 2018-12-03 | null | null | null | null | null | 309,237,645,462 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01894243 | Completed | 1 | 2014-03-13 | null | null | null | null | null | 326,417,514,702 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01894243 | Completed | 1 | 2014-03-13 | null | null | null | null | null | 326,417,514,702 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01894243 | Completed | 1 | 2014-03-13 | null | null | null | null | null | 326,417,514,702 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01894243 | Completed | 1 | 2014-03-13 | null | null | null | null | null | 326,417,514,702 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01894243 | Completed | 1 | 2014-03-13 | null | null | null | null | null | 326,417,514,702 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01894243 | Completed | 1 | 2014-03-13 | null | null | null | null | null | 326,417,514,702 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01894243 | Completed | 1 | 2014-03-13 | null | null | null | null | null | 326,417,514,702 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01894243 | Completed | 1 | 2014-03-13 | null | null | null | null | null | 326,417,514,702 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01894243 | Completed | 1 | 2014-03-13 | null | null | null | null | null | 326,417,514,702 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01894256 | Completed | 1 | 2013-11-01 | null | null | null | null | null | 403,726,927,788 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01894256 | Completed | 1 | 2013-11-01 | null | null | null | null | null | 403,726,927,788 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01894256 | Completed | 1 | 2013-11-01 | null | null | null | null | null | 403,726,927,788 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01894256 | Completed | 1 | 2013-11-01 | null | null | null | null | null | 403,726,927,788 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01894256 | Completed | 1 | 2013-11-01 | null | null | null | null | null | 403,726,927,788 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01894256 | Completed | 1 | 2013-11-01 | null | null | null | null | null | 403,726,927,788 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01894256 | Completed | 1 | 2013-11-01 | null | null | null | null | null | 403,726,927,788 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01894256 | Completed | 1 | 2013-11-01 | null | null | null | null | null | 403,726,927,788 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01894256 | Completed | 1 | 2013-11-01 | null | null | null | null | null | 403,726,927,788 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03318445 | Completed | 1 | 2018-01-12 | null | null | null | null | null | 609,885,356,962 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03318445 | Completed | 1 | 2018-01-12 | null | null | null | null | null | 609,885,356,962 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03318445 | Completed | 1 | 2018-01-12 | null | null | null | null | null | 609,885,356,962 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03318445 | Completed | 1 | 2018-01-12 | null | null | null | null | null | 609,885,356,962 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03318445 | Completed | 1 | 2018-01-12 | null | null | null | null | null | 609,885,356,962 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03318445 | Completed | 1 | 2018-01-12 | null | null | null | null | null | 609,885,356,962 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03318445 | Completed | 1 | 2018-01-12 | null | null | null | null | null | 609,885,356,962 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03318445 | Completed | 1 | 2018-01-12 | null | null | null | null | null | 609,885,356,962 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03318445 | Completed | 1 | 2018-01-12 | null | null | null | null | null | 609,885,356,962 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03101280 | Completed | 1 | 2017-04-27 | null | null | null | null | null | 678,604,834,304 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03101280 | Completed | 1 | 2017-04-27 | null | null | null | null | null | 678,604,834,304 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03101280 | Completed | 1 | 2017-04-27 | null | null | null | null | null | 678,604,834,304 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03101280 | Completed | 1 | 2017-04-27 | null | null | null | null | null | 678,604,834,304 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03101280 | Completed | 1 | 2017-04-27 | null | null | null | null | null | 678,604,834,304 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03101280 | Completed | 1 | 2017-04-27 | null | null | null | null | null | 678,604,834,304 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03101280 | Completed | 1 | 2017-04-27 | null | null | null | null | null | 678,604,834,304 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03101280 | Completed | 1 | 2017-04-27 | null | null | null | null | null | 678,604,834,304 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03101280 | Completed | 1 | 2017-04-27 | null | null | null | null | null | 678,604,834,304 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | null | null | 3 | null | null | null | null | Phase III+ | Phase II+ | 755,914,244,853 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | null | null | 3 | null | null | null | null | Phase III+ | Phase II+ | 755,914,244,853 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | null | null | 3 | null | null | null | null | Phase III+ | Phase II+ | 755,914,244,853 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | null | null | 3 | null | null | null | null | Phase III+ | Phase II+ | 755,914,244,853 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | null | null | 3 | null | null | null | null | Phase III+ | Phase II+ | 755,914,244,853 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | null | null | 3 | null | null | null | null | Phase III+ | Phase II+ | 755,914,244,853 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | null | null | 3 | null | null | null | null | Phase III+ | Phase II+ | 755,914,244,853 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | null | null | 3 | null | null | null | null | Phase III+ | Phase II+ | 755,914,244,853 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | null | null | 3 | null | null | null | null | Phase III+ | Phase II+ | 755,914,244,853 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01851265 | Completed | 1 | 2013-07-04 | null | null | null | null | null | 841,813,590,741 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01851265 | Completed | 1 | 2013-07-04 | null | null | null | null | null | 841,813,590,741 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01851265 | Completed | 1 | 2013-07-04 | null | null | null | null | null | 841,813,590,741 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01851265 | Completed | 1 | 2013-07-04 | null | null | null | null | null | 841,813,590,741 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01851265 | Completed | 1 | 2013-07-04 | null | null | null | null | null | 841,813,590,741 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01851265 | Completed | 1 | 2013-07-04 | null | null | null | null | null | 841,813,590,741 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01851265 | Completed | 1 | 2013-07-04 | null | null | null | null | null | 841,813,590,741 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01851265 | Completed | 1 | 2013-07-04 | null | null | null | null | null | 841,813,590,741 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01851265 | Completed | 1 | 2013-07-04 | null | null | null | null | null | 841,813,590,741 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01419548 | Withdrawn | 1 | 2011-07-29 | Withdrawn | stopped | null | null | null | 841,813,590,937 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01419548 | Withdrawn | 1 | 2011-07-29 | Withdrawn | stopped | null | null | null | 841,813,590,937 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01419548 | Withdrawn | 1 | 2011-07-29 | Withdrawn | stopped | null | null | null | 841,813,590,937 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01419548 | Withdrawn | 1 | 2011-07-29 | Withdrawn | stopped | null | null | null | 841,813,590,937 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01419548 | Withdrawn | 1 | 2011-07-29 | Withdrawn | stopped | null | null | null | 841,813,590,937 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01419548 | Withdrawn | 1 | 2011-07-29 | Withdrawn | stopped | null | null | null | 841,813,590,937 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01419548 | Withdrawn | 1 | 2011-07-29 | Withdrawn | stopped | null | null | null | 841,813,590,937 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01419548 | Withdrawn | 1 | 2011-07-29 | Withdrawn | stopped | null | null | null | 841,813,590,937 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01419548 | Withdrawn | 1 | 2011-07-29 | Withdrawn | stopped | null | null | null | 841,813,590,937 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03878095 | Recruiting | 2 | 2019-12-02 | null | null | null | null | Phase II+ | 1,022,202,217,130 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03878095 | Recruiting | 2 | 2019-12-02 | null | null | null | null | Phase II+ | 1,022,202,217,130 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03878095 | Recruiting | 2 | 2019-12-02 | null | null | null | null | Phase II+ | 1,022,202,217,130 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03878095 | Recruiting | 2 | 2019-12-02 | null | null | null | null | Phase II+ | 1,022,202,217,130 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03878095 | Recruiting | 2 | 2019-12-02 | null | null | null | null | Phase II+ | 1,022,202,217,130 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03878095 | Recruiting | 2 | 2019-12-02 | null | null | null | null | Phase II+ | 1,022,202,217,130 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03878095 | Recruiting | 2 | 2019-12-02 | null | null | null | null | Phase II+ | 1,022,202,217,130 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03878095 | Recruiting | 2 | 2019-12-02 | null | null | null | null | Phase II+ | 1,022,202,217,130 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT03878095 | Recruiting | 2 | 2019-12-02 | null | null | null | null | Phase II+ | 1,022,202,217,130 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01929603 | Completed | 1 | 2013-12-01 | null | null | null | null | null | 1,022,202,217,519 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01929603 | Completed | 1 | 2013-12-01 | null | null | null | null | null | 1,022,202,217,519 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01929603 | Completed | 1 | 2013-12-01 | null | null | null | null | null | 1,022,202,217,519 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 4 | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01929603 | Completed | 1 | 2013-12-01 | null | null | null | null | null | 1,022,202,217,519 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01929603 | Completed | 1 | 2013-12-01 | null | null | null | null | null | 1,022,202,217,519 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01929603 | Completed | 1 | 2013-12-01 | null | null | null | null | null | 1,022,202,217,519 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01929603 | Completed | 1 | 2013-12-01 | null | null | null | null | null | 1,022,202,217,519 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | europepmc | literature | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01929603 | Completed | 1 | 2013-12-01 | null | null | null | null | null | 1,022,202,217,519 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | chembl | known_drug | 413,311 |
ENSG00000041880 | EFO_0000616 | NCT01929603 | Completed | 1 | 2013-12-01 | null | null | null | null | null | 1,022,202,217,519 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF tolerant | Detected in all | Low tissue specificity | from1to10 | expression_atlas | rna_expression | 413,311 |